Domov › Difúzny veľkobunkový B-lymfóm › Maryland
Klinické štúdie Difúzny veľkobunkový B-lymfóm v štáte Maryland
13 štúdií pre Difúzny veľkobunkový B-lymfóm hľadá účastníkov v zariadeniach v štáte Maryland.
Mestá v štáte Maryland
Oficiálny text štúdie (anglicky)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
- The Center for Cancer and Blood Disorders, Bethesda
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06500273Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06649812A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- American Oncology Partners of Maryland Pa, Bethesda
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05006716Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
Prebieha náborFáza 1/2
Vek 18 až 120 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT03223610A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- American Oncology Partners, P.A. ( Site 0185), Bethesda
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06091865Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT04002947Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
Prebieha náborFáza 1
Vek 18 až 120 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT05389423Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 7. 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 7. 2026 · NCT05131022A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 3. 2026 · NCT04830137Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 2. 2026 · NCT05633615Z ClinicalTrials.gov, dáta načítané 4. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.